CNS.4U – Human iPS Cell-Derived Central Nervous System Cells

CNS4U-human iPS Cell-Derived Central Nervous System CellsImmunofluorescence staining of beta-3-tubulin in CNS.4UTM

 

CNS.4U characteristics

  • Physiological co-culture of CNS neurons and astrocytes
  • Stable culture over 5 weeks; neural network formation as of day 18
  • Suitable as seizure liability model given long-term synchronous network activity and reactivity to seizure-active compounds

CNS.4U form highly physiological networks comprising of dopaminergic, glutamatergic and GABAergic neurons as well as astrocytesCNS.4U cell type composition. CNS.4U form highly physiological networks comprising of dopaminergic, glutamatergic and GABAergic neurons as well as astrocytes (left to right)

CNS.4UTM represent a highly physiological in vitro co-culture model of neurons and astrocytes for a range of drug development, neurotoxicity and disease modeling applications. CNS.4UTM comprise two key cell types of the human central nervous system (CNS): neurons (glutamatergic, GABAergic and dopaminergic) and astrocytes. The cells are simultaneously generated from neural precursor cells and recapitulate the interplay between excitatory and inhibitory neurons. Their rapid formation of neuronal networks, prolonged viability in culture, and availability in unlimited volumes, makes CNS.4UTM advantageous compared to currently used primary cell and animal models for neuroscience-related applications. CNS.4UTM represent an ideal tool for early & late drug discovery for neurodegenerative disease and epilepsy, in vitro neurotoxicity assays, and disease modeling, through electrophysiological, metabolic and imaging-based assays. Axiogenesis is member of the FDA - HESI Neurotox for seizure liability; CNS.4UTM will be validated through this initiative.

 

CNS.4UTM network formation. 10x magnification. 20 minutes to 60 hours after seeding

 

CNS.4U synchronous activity is maintained over 5 weeks in culture 

MEA at day 34 heatmap (left): All electrodes are illuminated at the same time indicating synchronous activity in all recordings

 

CNS.4U are suitable for seizure liability

CNS4U_MEA_Seizure_disease_modeling_effects of seizure-inducing compound Picrotoxin and seizure-reducing compound Phenotyoin.CNS.4UTM for seizure disease modeling. MEA technology was used to assess effects of seizure-inducing compound Picrotoxin and seizure-reducing compound Phenytoin. A shows exemplary raw data (individual MEA plate wells) at different times after drug application. B shows quantification of data at timepoint 60min. Compound effects are statistically significant (student’s t-test; p=0.05)

 

CNS.4U have been validated in the following assays and applications:

FIND US

Nattermannallee 1, Bldg S20
50829 Cologne
Germany –  (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)

EMAIL US

Orders: order@axiogenesis.com
Support: support@axiogenesis.com
Other: office@axiogenesis.com

FOLLOW US

Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter

CALL US

Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10